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HIGHLIGHTS
 Neurohormonal dysfunction (increased
sympathetic nervous system and renin
angiotensin-aldosterone system) play an
important role in pulmonary hypertension
progression.
 In this proof-of-concept study we
demonstrated in 2 pulmonary hyperten-
sion rat models that renal denervation
therapy improved pulmonary vascular
remodeling, lowered right ventricular
afterload, and decreased right ventricular
stiffness.
 Renal denervation effects may be
associated with a suppression of the
renin-angiotensin-aldosterone system.
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SUMMARY
Neurohormonal overactivation plays an important role in pulmonary hypertension (PH). In this context, renal
denervation, which aims to inhibit the neurohormonal systems, may be a promising adjunct therapy in PH. In
this proof-of-concept study, we have demonstrated in 2 experimental models of PH that renal denervation
delayed disease progression, reduced pulmonary vascular remodeling, lowered right ventricular afterload, and
decreased right ventricular diastolic stiffness, most likely by suppression of the renin-angiotensin-aldosterone
system. (J Am Coll Cardiol Basic Trans Science 2017;-:-–-) © 2017 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
P ulmonary hypertension (PH) is a fataldisease characterized by excessivepulmonary vascular remodeling and
increased right ventricular (RV) afterload,
subsequently leading to RV maladaptive
remodeling and failure (1,2).
Neurohormonal mediators, such as the sympathetic
nervous system (SNS) and renin angiotensin-
aldosterone system (RAAS) are involved in the pro-
gression of PH and may contribute to pulmonary
vascular remodeling and RV dysfunction (3–6). In-
creased levels of SNS activity have been reported in PH
patients (7,8) and are associated with disease pro-
gression and prognosis (9). Previously reported evi-
dence by our group and others showed that systemic
(10) and local (11) RAAS activities are increased in PH
patients and are also associated with disease progres-
sion (4). Additionally, we demonstrated that chronic
angiotensin II type 1 (AT1)–receptor blocker treatment
delayed disease progression, reduced pulmonary
vascular remodeling, and improved RV diastolic
function in a PH animal model (4). Furthermore, pre-
vious studies in experimental PH provided evidence
that modulation of the sympathetic system improved
RV systolic function (12,13) and pulmonary vascular
remodeling (12,14). Therefore, targeting the RAAS and
SNS could be a promising therapy in PH (1,3,5).
In this context, renal denervation (RD) might be
pertinent. RD aims to abolish afferent and efferent
renal nerve signaling (15–17). Afferent renal nerve
activation is sympathoexcitatory (18,19), whereas
renal efferent nerve activation results in vasocon-
striction, sodium retention, release of renin from the
juxtaglomerular cells, and contributes to angiotensin
II and aldosterone production (20,21), both of which
exacerbate PH. In the present study, we investigate
the effect of RD treatment on pulmonary vascular
remodeling and cardiac function in 2 well-established
PH animal models (4,22,23).
METHODS
All experiments were approved by the Institutional
Animal Care and Use Committee of the VU University,
Amsterdam, the Netherlands (FYS 13-05 and 14-10)
and performed according to the Declaration of Hel-
sinki conventions for the use and care of animals.
EXPERIMENTAL PH. In this study we investigated
the effects of RD-therapy in 2 PH animal models:
monocrotaline (MCT) and sugen 5416 combined with
chronic hypoxia (SuHx) (4,22,23). PH status was
conﬁrmed by echocardiography at week 2 (MCT
model) and week 6 (SuHx model); at this point
animals were randomized to sham surgery or RD
surgery. At end-of-study (week 6 for MCT; week 10 for
SuHx, or when animals manifest signs of right heart
failure), echocardiography and RV catheterization
with pressure-volume analyses were performed. An
overview ﬂow of the study design can be found in
Supplemental Figure S1A and S1B (4,13).
SURGICAL RD. Thirty minutes before anesthesia
(isoﬂurane induction: 4.0% in 1:1 O2/air mix; main-
tenance: 2.0% in 1:1 O2/air mix), rats received an
injection of analgesia (buprenorphine; 0.1 mg/kg
subcutaneously). Bilateral ﬂank incisions were per-
formed and the kidneys were approached retroperi-
toneally. The renal arteries and veins were stripped
from the adventitia. All visible renal nerve bundles
were cut under a dissection microscope (25X) and
the vessels were coated with a solution of 10%
ABBR EV I A T I ON S
AND ACRONYMS
AT1 = angiotensin II type 1
Ea = right ventricular afterload
Eed = right ventricular
stiffness
Ees = right ventricular
contractility
MCT = monocrotaline model
PH = pulmonary hypertension
RAAS = renin angiotensin-
aldosterone system
RD = renal denervation
SNS = sympathetic nervous
system
SuHx = sugen combined with
hypoxia model
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phenol in ethanol (24). In the sham group, the same
surgical procedure was performed, but renal nerves
remained intact and no phenol solution was used.
Analgesic (carprofen; 4.0 mg/kg subcutaneously)
was used directly after surgery, and 24 h and 48 h
after the procedure. The animals recovered from
the surgery within 1 week. The efﬁcacy of this pro-
cedure was evaluated by measuring renal tissue
norepinephrine content, assessed by enzyme-linked
immunosorbent assay (Alpco Diagnostics, Salem,
New Hampshire, No 17-NORHU-E01-RES), and
normalized to protein concentration.
RV PRESSURE-VOLUME RELATIONSHIPS. RV open-
chest catheterization was performed using a com-
bined pressure-volume catheter (SPR-869, Millar
Instruments, Houston, Texas). Details regarding the
RV catheterization can be found online in the
Supplemental Material and Methods section. Stroke
volume (in relative volume units) obtained from the
conductance catheter was calibrated using the echo-
cardiogram stroke volume (in ml). Using custom-
made algorithms (programmed in MATLAB 2007b,
The MathWorks, Natick, Massachusetts) RV (peak-)
systolic pressures and RV end-diastolic pressures
were automatically determined from RV catheteriza-
tion steady-state measurements, as well as arterial
elastance (Ea), a measurement of RV afterload (25).
From vena cava occlusion, end-systolic elastance
(Ees) (RV contractility) and end-diastolic elastance
(Eed) (RV stiffness) were determined (13). These
parameters represent the slope of end-systolic and
end-diastolic pressure-volume relationships, and are
considered load-independent measurements for car-
diac contractility (Ees) and stiffness (Eed) (26). The
ratio Ees/Ea was calculated, and it represents the
RV-arterial coupling.
HISTOMORPHOLOGY OF HEART AND LUNGS. After hemo-
dynamic evaluation, rats were euthanized by exsan-
guination under isoﬂurane. Heart, lungs, and other
major organs were harvested. Cardiomyocyte cross-
sectional area, cardiac ﬁbrosis, and relative wall
thickness of pulmonary arterioles were determined.
CARDIOMYOCYTE CROSS-SECTIONAL AREA. Hema-
toxylin and eosin–stained cardiac cryosections (5 mm)
were used to determine left ventricular (LV) and RV
cardiomyocyte cross-sectional area (CSA). Car-
diomyocyte size for each ventricle was expressed as
the average CSA of minimally 20 transversally cut
cardiomyocytes at the level of the nucleus, randomly
distributed over the ventricles.
CARDIAC FIBROSIS. The combination of Picrosirius
red staining (5 mm) and polarized light was used for
analysis of cardiac ﬁbrosis (27). LV and RV ﬁbrosis
were expressed as the percentage tissue area positive
for collagen, measured over minimally 5 random
areas per ventricle.
RELATIVE WALL THICKNESS OF PULMONARY
ARTERIOLES. Lung cryosections (5 mm) were stained
with Elastica van Gieson for morphometric analysis
of vascular dimensions. Minimally, 50 transversal
pulmonary arterioles with an outer diameter be-
tween 25 mm and 100 mm, were randomly
measured over the lungs. Media and intima wall
thickness were measured in duplicate as described
previously (23).
IMMUNOFLUORESCENCE AND PROTEIN EXPRESSION.
AT1-receptor, mineralocorticoid receptor (MR) den-
sity, and proliferation activity (Ki67) were evaluated
by immunoﬂuorescence in the pulmonary vascula-
ture. In addition, AT1 and MR receptor expression
were measured in the RV homogenates by Western
blot (Supplemental Material and Methods).
STATISTICAL ANALYSIS. Statistical analyses were
performed using Prism for Windows (GraphPad 6
Software San Diego, California). Data are presented
as mean  SEM. Values of p < 0.05 were considered
signiﬁcant. All variables were visually checked for
normal distribution by appreciation of the histogram
and comparing mean versus median value (which
should be about the same) and standard deviation
(SD) versus the mean (2 $ SD < mean). Data that
failed these criteria were log-transformed and these
log-transformed data were again visually checked
using the same criteria. For the MCT model, the
following variables were log-transformed: Eed, per-
centage of open/fully occluded vessels, immunoﬂu-
orescence for AT1 and MR receptors, and Western
blot analysis for MR receptor. For the SuHx-model,
the following variables were log-transformed: Ees,
percentage of open/fully occluded vessels, and
immunoﬂuorescence for Ki67. Comparison between
echocardiography analyses before and after RD
treatment was performed by 2-way analysis of vari-
ance (ANOVA) for repeated measurements followed
by the Bonferroni post-hoc test. One-way ANOVA
with Bonferroni post-hoc comparison between sham
and RD groups was used for pressure-volume re-
lationships, autopsy data, and protein analyses.
Histology data were analyzed using multilevel anal-
ysis to correct for nonindependence of successive
measurements per animal (MLwiN 2.02.03, Center
for Multilevel Modeling, Bristol, United Kingdom)
(4,13,22,28,29).
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RESULTS
GENERAL HEMODYNAMIC EFFECTS OF RD IN
EXPERIMENTAL PH. All MCT rats and 1 SuHx rat
developed early signs of heart failure at week 4
and week 8, respectively. The efﬁcacy of RD
was conﬁrmed by a signiﬁcant reduction of norepi-
nephrine levels in kidney tissue (Supplemental
Figures S2A and S2B). Renal norepinephrine levels
were reduced by 97% (MCT) and 81% (SuHx).
However, measured under anesthesia, the systolic
and diastolic blood pressures and systemic vascular
resistance were signiﬁcantly reduced after RD
(Tables 1 and 2), whereas no effect in heart rate or in
RV end-systolic pressure were observed after RD
treatment (Tables 1 and 2). Other than the hypoten-
sive effect of RD therapy, no macroscopic kidney
damage, kidney mass (Supplemental Tables S1
and S2), or signs of animal discomfort were observed.
Before surgery was performed, PH development in
both models was conﬁrmed by echocardiography
(Supplemental Tables S3 and S4, Figure 1). After RD
surgery, echocardiographic measurements showed a
signiﬁcant delay in disease progression in RD-PH rats
(Figure 1). Pulmonary vascular resistance and RV wall
thickness (Figures 1A to 1D) was signiﬁcantly reduced
in both models after RD treatment in comparison to
the sham group. However, no signiﬁcant effects in RV
end-diastolic diameter, tricuspid annular plane sys-
tolic excursion, and cardiac output were observed
(Figures 1E to 1J).
RD REDUCED RV AFTERLOAD AND RV DIASTOLIC
STIFFNESS. To assess the effect of RD on load-
independent parameters of RV function, we per-
formed RV pressure-volume analyses at the end of
the study (representative pressure-volumes can be
found in Figures 2A to 2C and 3A to 3C). RD signiﬁ-
cantly reduced RV afterload (Ea) (Figures 2D and 3D)
and RV stiffness (Eed) (Figures 2F and 3F) without
signiﬁcant effect in RV relaxation (dP/dt min and Tau)
(Tables 1 and 2). Although not statistically signiﬁcant,
we observed a minor reduction in RV contractility
TABLE 1 Hemodynamic Data for the Monocrotaline Model
Control
(n ¼ 5)
MCT-Sham
(n ¼ 9)
MCT-RD
(n ¼ 9)
p Value
Control vs. MCT MCT vs. RD
RV end-systolic pressure (mm Hg) 27  2.5 66  2.9 61  2.3 <0.001 0.35
RV end-diastolic pressure (mm Hg) 2.8  0.6 3.9  0.6 3.3  0.3 0.57 0.97
dP/dt maximum (mm Hg/s) 1,681  218 2,732  170 2,554  126 <0.001 0.42
dP/dt minimum (mm Hg/s) –1,293  174 –2,366  141 –2,405  100 <0.001 0.83
Tau (ms) 11  2.5 13  1.0 12  0.4 0.32 0.46
Systolic blood pressure (mm Hg) 102  6.6 88  3.1 75  3.3 0.15 0.03
Diastolic blood pressure (mm Hg) 67  7.9 65  2.6 51  3.2 >0.999 0.03
SVR (mm Hg$min$ml-1) 0.6  0.1 1.9  0.3 1.1  0.1 0.002 0.01
Heart rate (beats/min) 300  11.4 317  5.5 300  13.7 >0.999 0.30
Values are mean  SEM. One-way ANOVA followed by Bonferroni correction.
MCT ¼ monocrotaline; RD ¼ renal denervation; RV ¼ right ventricle; SVR ¼ systemic vascular resistance; Tau ¼ isovolumic relaxation constant.
TABLE 2 Hemodynamic Data for the Sugen þ Hypoxia Model
Control
(n ¼ 6)
SuHx-sham
(n ¼ 10)
SuHx-RD
(n ¼ 10)
p Value
Control vs. SuHx SuHx vs. RD
RV end-systolic pressure (mm Hg) 24  0.93 60  3.3 56  3.3 <0.001 0.39
RV end-diastolic pressure (mm Hg) 1.9  0.09 2.7  0.4 3.3  0.4 0.56 0.22
dP/dt maximum (mm Hg/s) 1,149  40 2,515  142 2,733  210 <0.001 0.34
dP/dt minimum (mm Hg/s) –953  43 –2,092  146 –2,267  202 <0.001 0.43
Tau (ms) 5.1  0.45 10.1  0.79 10.7  0.88 <0.001 0.63
Systolic blood pressure (mm Hg) 86  3.5 90  6.71 80  4.1 >0.999 0.17
Diastolic blood pressure (mm Hg) 59  3.2 66  7.1 54  3.9 >0.999 0.12
SVR (mm Hg$min$ml–1) 0.7  0.03 1.3  0.2 0.9  0.09 0.01 0.03
Heart rate (beats/min) 261  8.5 274  10.1 249  9.5 >0.999 0.21
Values are mean  SEM. One-way ANOVA followed by Bonferroni correction.
SuHx ¼ sugen þ hypoxia; other abbreviations as in Table 1.
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FIGURE 1 Renal Denervation Signiﬁcantly Delayed Disease Progression in Both Animal Models
RD reduced signiﬁcant pulmonary vascular resistance (A: MCT model; B: SuHx model). In addition, RD delayed the RV hypertrophy (C: MCT;
D: SuHx). No changes were observed in RV end-diastolic diameter (E:MCT; F: SuHx) and in RV function (G:MCT; H: SuHx) or in cardiac output
(I:MCT; J: SuHx). On the right side: Control: n ¼ 5, MCT-sham: n ¼ 9, and MCT-RD: n ¼ 9. On the left side: Control: n ¼ 6, SuHx-sham: n ¼ 10,
and SuHx-RD: n ¼ 10. Data presented as mean  SEM. Two-way ANOVA for repeated measurements followed by Bonferroni correction.
Arrows indicate the interaction from 2-way ANOVA. ANOVA ¼ analysis of variance; CO ¼ cardiac output; MCT ¼ monocrotaline;
PVR ¼ pulmonary vascular resistance; RD ¼ renal denervation; RV ¼ right ventricular; RVEDD ¼ right ventricle end-diastolic diameter;
RVWT¼ right ventricle wall thickness; SuHx ¼ sugen þ hypoxia; TAPSE ¼ tricuspid annular plane systolic excursion.
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(Ees) (Figures 2E and 3E) and a minor increase in RV
arterial coupling after RD (Ees/Ea-MCT: 0.60  0.05
vs. 0.50  0.10; p ¼ 0.45; SuHx: 0.80  0.09 vs. 0.60 
0.07; p ¼ 0.13) .
RD REDUCED PULMONARY VASCULAR AND RV
REMODELING. Analysis of pulmonary vascular and
RV morphometry was performed to conﬁrm changes
in RV afterload and remodeling at the tissue level.
Histological analyses from the relative wall thickness
of pulmonary arterioles indicated a signiﬁcant reduc-
tion in media wall thickness in both models
(Figures 4C and 4D), and reduced intima wall thickness
in the SuHx model (Figure 4E). Moreover, RD treat-
ment decreased the formation of occlusive vascular
lesions in both PH models (Figures 4F and 4G).
RV cardiomyocyte CSA was signiﬁcantly reduced
in both models due to RD (Figure 5); however, no effect
on LV cardiomyocyte CSAwas observed (Supplemental
Tables S1 and S2). Furthermore, we observed a signif-
icant reduction of RV ﬁbrosis in the SuHx-RD group
(Figure 5F), but this ﬁnding was not signiﬁcant neither
in the MCT model (Figure 5E) nor in the LV from both
models (Supplemental Tables S1 and S2).
AT1 RECEPTOR EXPRESSION AND CELL PROLIFERATION
WERE REDUCED AFTER RD. To further investigate the
effects of RD on pulmonary vascular remodeling, we
assessed changes in local AT1 receptor and cell pro-
liferation (Ki67) by immunoﬂuorescence staining of
pulmonary arterioles. After RD therapy, the staining
demonstrated a reduction of AT1 receptor density in
pulmonary arterial smooth muscle cells (Figures 6A
to 6D) and the rate of proliferative cells (Figures 7A
to 7D) in both PH rat models. Moreover, to investi-
gate the effects of RD on the RV remodeling, we also
assessed changes in AT1 receptor expression in RV
homogenates. Western blot analyses of RV homoge-
nates revealed reduced expression of the AT1 recep-
tor in the MCT model (Figure 8A), but not in the
SuHx model (Figure 8B). These data might suggest
that the effects of RD on RV afterload and pulmonary
vascular remodeling could be associated with
reduced AT1 receptor density in pulmonary arterial
smooth muscle cells.
MR EXPRESSION WAS REDUCED AFTER RD. Besides
changes in angiotensin II signaling, reduced aldoste-
rone signaling may also contribute to the beneﬁcial
effects of RD. Aldosterone can promote vascular and
RV remodeling via MR binding. Here we measured MR
density in lungs by immunoﬂuorescence and MR
expression in RV byWestern blot.We observed that RD
was able to reduced local MR density in the pulmonary
vasculature in the SuHx model (Figures 6E to 6H).
FIGURE 2 Pressure-Volume Analyses in Monocrotaline Model
Representative examples of pressure-volume relationship for control, MCT-sham, and MCT-RD groups (A to C). RD signiﬁcantly reduced RV
afterload (D), without affecting RV contractility (E) and reduced RV stiffness (F). Control: n ¼ 5, MCT-sham: n ¼ 9, and MCT-RD: n ¼ 9. Data
are presented as mean  SEM. One-way ANOVA followed by Bonferroni correction. Ea ¼ RV afterload; Eed ¼ RV stiffness; Ees ¼ RV
contractility; other abbreviations as in Figure 1.
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Moreover, RD reduced the MR expression in RV
homogenates of both PH rat models (Figures 8C
and 8D). This might suggest that observed changes in
RV diastolic stiffness, RV hypertrophy, and ﬁbrosis
could be related to reduced local MR-expression.
DISCUSSION
This study investigated the effects of RD on pulmo-
nary vascular remodeling and RV function. Using
2 well-established PH animal models, MCT and SuHx,
we demonstrated that: 1) RD delayed disease pro-
gression; 2) RD reduced RV afterload and pulmonary
vascular remodeling; 3) RD reduced diastolic stiff-
ness, hypertrophy, and ﬁbrosis of the RV; and 4)
Beneﬁcial effects of RD could be associated with
RAAS suppression.
RD DELAYED PH PROGRESSION AND REDUCED
PULMONARY VASCULAR REMODELING. RD is a
widely studied novel treatment modality for resistant
systemic hypertension. By applying radiofrequency
energy along the length of the main renal arteries to
ablate the renal nerves, sympathetic overactivation
(24,30) and renin release of the kidney (31) can be
prevented in humans.
Recent studies have revealed that both the SNS as
well as the RAAS are upregulated and closely
associated to disease progression in PH patients (4).
However, whether RD may be clinically beneﬁcial in
PH patients is currently unclear.
Promising beneﬁcial effects of RD have been
published recently in a canine model for PH (32,33).
In contrast to our study, they initiated treatment
before PH development, which limits the clinical
translation of their ﬁndings. Therefore, we performed
a therapeutic study with RD in 2 well-established PH
animal models, the MCT and SuHx rat models. We
demonstrated that chronic RD treatment delayed
disease progression and reduced pulmonary vascular
remodeling and proliferation in both animal models.
Previous data from our group revealed that both
systemic as well as local RAAS activity is increased
in PH patients and closely related to disease pro-
gression (4). Speciﬁcally, altered expression of the
AT1 receptor was identiﬁed as a key regulator of
increased RAAS in the pulmonary vasculature
because its acute and chronic inhibition resulted in
marked improvements in pulmonary vascular
remodeling and smooth muscle cell proliferation (4).
Therefore, to investigate whether changes in local
RAAS could explain the delayed disease progression
and pulmonary vascular remodeling after RD, we
assessed AT1 receptor density and cell proliferation
in both models. Intriguingly, RD was able to reduce
FIGURE 3 Pressure-Volume Analyses in Sugen þ Hypoxia Model
Representative examples of pressure-volume relationship for control, SuHx-sham and SuHx-RD groups (A to C). RD signiﬁcantly reduced Ea
(D), without affecting Ees (E) and reduced Eed (F). Control: n ¼ 6, SuHx-sham: n ¼ 10, SuHx-RD: n ¼ 10. Data are presented as mean  SEM.
One-way ANOVA followed by Bonferroni correction. Abbreviations as in Figures 1 and 2.
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FIGURE 4 Renal Denervation Reduced the Pulmonary Vascular Remodeling
Representative examples of pulmonary arterioles (Elastica van Gieson) (scale bar, 20 mm). (A) Examples from the MCT model. (B) Examples
from the SuHx model. RD reduced signiﬁcantly the wall thickness of the pulmonary arterioles, as observed by a reduction in both the media
(C: MCT; D: SuHx), and intima layers (E: SuHx). In addition, RD increased signiﬁcantly the percentage of open vessels and reduced the number
of full obliterated vessels in both PH-models (F: MCT; G: SuHx). A: Control: n ¼ 5, MCT-sham: n ¼ 9, and MCT-RD: n ¼ 9; B: Control: n ¼ 6,
SuHx-sham: n ¼ 10, and SuHx-RD: n ¼ 10. Data are presented as mean  SEM. Multilevel analysis to correct for non-independence of
successive measurements per animal. FO ¼ fully obliterated vessels; PO ¼ partially obliterated vessels; other abbreviations as in Figure 1.
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AT1 receptor density and the rate of proliferative
cells. These data suggest that the beneﬁcial effect of
RD on pulmonary vascular remodeling could be
partly explained by reduced AT1 receptor expression
in PH rats. This is further supported by the observa-
tion that the results of RD are very similar to the
previous reported effects of the angiotensin receptor
blocker (losartan) in the MCT model (4), but not to
the previous reported effects of beta-blockade (biso-
prolol) (13). Nevertheless, the exact mechanisms by
which RD improved the pulmonary vascular remod-
eling and RV diastolic stiffness in PH remain unclear.
FIGURE 5 Renal Denervation Reduced Right Ventricular Hypertrophy and Fibrosis
Representative examples of RV cross-sectional area (hematoxylin and eosin stain) and ﬁbrosis (Picrosirius red stain) (scale bar, 20 mm).
(A) Examples from an MCT-treated animal. (B) Examples from a SuHx model. RD reduced signiﬁcantly the RV cross-sectional area (C: MCT;
D: SuHx). RD reduced the RV ﬁbrosis, specially in the SuHx-model (E: MCT; F: SuHx). Right side: Control: n ¼ 5, MCT-sham: n ¼ 9, and
MCT-RD: n ¼ 9. Left side: Control: n ¼ 6, SuHx-sham: n ¼ 10, and SuHx-RD: n ¼ 10. Data are presented as mean  SEM. Multilevel analysis
has been performed to correct for non-independence of successive measurements per animal. Abbreviations as in Figure 1.
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FIGURE 6 Angiotensin II Type 1 Receptor and Mineralocorticoid Density in the Pulmonary Vasculature
Representative images for AT1-receptor and MR-receptor immunoﬂuorescence staining. (A) Examples from the MCT animal model.
(B) Examples from the SuHx model. AT1-receptor (red), smooth muscle cells (SM22) (green), and nuclei (DAPI) (scale bar, 20 mm). (C and D)
RD reduced AT1-receptor density in the pulmonary vasculature. (E) Examples from the MCT animal model. (F) Examples from the SuHx model:
MR-receptor (red), SM22 (green), and nuclei (DAPI) (scale bar, 20 mm). (G and H) RD reduced MR-receptor density in the pulmonary
vasculature in the SuHx-model. Control: n ¼ 4, MCT-sham: n ¼ 4, and MCT-RD: n ¼ 4. Control: n ¼ 4, SuHx-sham: n ¼ 4, and SuHx-RD:
n ¼ 4. Data are presented as mean  SEM. One-way ANOVA followed by Bonferroni correction. AT1¼ angiotensin II type 1 receptor;
DAPI ¼ 40,6-diamidino-2-phenylindole; MR ¼ mineralocorticoid receptor; SM ¼ smooth muscle; other abbreviations as in Figure 1.
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In this proof-of-concept study, we provided some
evidence that RD therapy in experimental PH may
have some suppressive effect on RAAS. Despite the
effects of RD on the RAAS, RD may also have effects
on the SNS, which should be further explored in the
PH context.
RD REDUCED RV DIASTOLIC STIFFNESS. Previous
studies in resistant hypertensive patients have shown
that catheter-based RD reduced LV hypertrophy and
improved LV diastolic function independently of
blood pressure and heart rate reduction (34–36).
Furthermore, experimental studies in hypertensive
and chronic pressure overload rat models demon-
strated that RD was able to ameliorate LV maladap-
tive remodeling (37,38).
In the current study, we provide evidence that RD
improved RV diastolic stiffness and RV remodeling in
PH rats. We observed no signiﬁcant changes in RV
relaxation (dP/dt min, Tau), which do not necessarily
correlate with RV stiffness (39).
Recently, we demonstrated that in severe PH, in
addition to the myoﬁbril stiffness, ﬁbrosis also
contributed to increase RV diastolic stiffness (40). One
of the contributors of cardiac ﬁbrosis and hypertrophy
is the activation of MR, which could be mediated via
aldosterone. Until now, little is known about the
contribution of aldosterone activity and MR receptor
on RV function and remodeling in PH. Important ob-
servations fromMaron et al. (10,41) previously showed
that aldosterone serum levels were increased in PH
patients, as well as animal models of PH, and these
levels were associated with cardiac dysfunction.
In this study we observed increased expression of the
MR receptor in the right ventricle of PH in comparison
to control. In addition, RD was able to restore MR
receptor expression, suggesting that RD could
improve RV diastolic stiffness by reducing RV ﬁbrosis
via MR restoration in the RV.
STUDY LIMITATIONS. Although neurohormonal in-
hibitors may have some efﬁcacy in experimental PH
(4,42), their side effects may hamper their clinical
translation. In this proof-of-concept study, we
demonstrated that neurohormonal inhibition by sur-
gical RD was able to improve the pulmonary vascular
FIGURE 7 Proliferation Activity in the Pulmonary Vasculature
Representative images for Ki67 immunoﬂuorescence staining. (A) Examples from the MCT animal model. (B) Examples from the SuHx model.
Ki67 (white),a-smoothmuscle actin (red),nuclei (DAPI) (scale bar, 20mm). (C andD)RD reduced the proliferation in the pulmonary vasculature.
Control: n¼ 4,MCT-sham: n¼ 5, andMCT-RD: n¼ 4. Control: n¼ 4, SuHx-sham: n¼ 4, and SuHx-RD: n¼ 4. Data are presented asmean SEM.
One-way ANOVA followed by Bonferroni correction. Ki67 ¼ cell proliferation marker; other abbreviations as in Figures 1 and 6.
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remodeling and RV diastolic stiffness in 2 PH animal
models, but this coincided with a decrease in sys-
temic blood pressure. Although no other signs of
discomfort were noticed, the ﬁnding of systemic
hypotension is alarming and may limit the clinical
translation of RD in clinical PH.
One limitation of our pressure-volume analyses is
that we cannot obtain the absolute end-systolic/
-diastolic volumes; therefore, some parameters
cannot be estimated (e.g., the pressure-volume loop
intercept, V0). However, the reported PV-derived
parameters Ees, Eed, and Ea only rely on absolute
changes in volumes, and do not depend on absolute
volume measurements. Finally, we cannot exclude
the possibility that renal denervation may have
resulted in a small but clinically relevant increase in
RV end-diastolic volume that we were not able to
detect by echocardiography.
CONCLUSIONS
Using 2 well-established PH animal models, we pro-
vided evidence that chronic RD treatment delayed
disease progression. RD reduced pulmonary vascular
FIGURE 8 Angiotensin II Type 1 Receptor and Mineralocorticoid Receptor Expression in Right Ventricle Tissue
(A) Western blot analyses revealed signiﬁcant reduction of AT1-receptor expression in the RV homogenates after RD in the MCT model in
comparison to the sham-group. (B) However, no signiﬁcant reduction was found in AT1-receptor expression in the SuHx model. (C and D)
After RD, Western blot analyses revealed a signiﬁcant reduction in the expression of MR-receptor in the SuHx-model. Protein expression was
normalized by GAPDH, as a loading control. On right side: Control: n ¼ 5, MCT-sham: n ¼ 7, MCT-RD: n ¼ 9; on the left side: Control: n ¼ 6,
SuHx-sham: n ¼ 8 and SuHx-RD: n ¼ 8. Data are presented as mean  SEM. One-way ANOVA followed by Bonferroni correction.
GAPDH ¼ glyceraldehyde 3-phosphate dehydrogenase; other abbreviations as in Figures 1 and 6.
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resistance, RV afterload, pulmonary vascular
remodeling, and RV diastolic stiffness. These bene-
ﬁcial effects could be associated with a partial sup-
pression of RAAS after RD, as revealed by both a
down-regulation of AT1 receptors in the pulmonary
vasculature and a reduction of MR expression in RV
homogenates.
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